Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers Health, Inc. (NYSE:HIMS) stock is trading lower on Wednesday, with a session volume of 7.7 million compared to ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

Investing.com -- Shares of Hims and Hers (NYSE: HIMS) fell 3% amidst news of Novo Nordisk (NYSE: NVO) introducing NovoCare Pharmacy, which directly impacts the competitive landscape by offering ...

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...

Hims & Hers has bet big on prescribing compounded versions of these drugs, including by buying its own compounding pharmacy in September. The FDA has allowed pharmacies to make compounded versions ...

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a buy.